Unione Europea - italiano - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - reiezione del trapianto - immunosoppressori - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

xiromed sa - rosuvastatinum - compresse rivestite con film - filmtablette: rosuvastatinum 5 mg ut rosuvastatinum calcicum, cellulosum microcristallinum, silica colloidalis anhydrica, crospovidonum, cellulosum microcristallinum, lactosum monohydricum 100.915 mg, magnesii stearas, Überzug: hypromellosum, e 171, lactosum monohydricum 0.945 mg, triacetinum, e 172 (flavum) pro compresso obducto. - riduzione della serumcholesterinkonzentration - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

xiromed sa - rosuvastatinum - compresse rivestite con film - filmtablette: rosuvastatinum 10 mg ut rosuvastatinum calcicum, cellulosum microcristallinum, silica colloidalis anhydrica, crospovidonum, cellulosum microcristallinum, lactosum monohydricum 95.706 mg, magnesii stearas, Überzug: hypromellosum, e 171, lactosum monohydricum 1.08 mg, triacetinum, e 172 (rubrum) pro compresso obducto. - riduzione della serumcholesterinkonzentration - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

xiromed sa - rosuvastatinum - compresse rivestite con film - filmtablette: rosuvastatinum 20 mg ut rosuvastatinum calcicum, cellulosum microcristallinum, silica colloidalis anhydrica, crospovidonum, cellulosum microcristallinum, lactosum monohydricum 191.412 mg, magnesii stearas, Überzug: hypromellosum, e 171, lactosum monohydricum 2.16 mg, triacetinum, e 172 (rubrum) pro compresso obducto. - riduzione della serumcholesterinkonzentration - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - rosuvastatinum - compresse rivestite con film - rosuvastatinum 5 mg ut rosuvastatinum calcicum, lactosum monohydricum 47.696 mg, calcii carbonas, cellulosum microcristallinum, crospovidonum, hydroxypropylcellulosum, magnesii stearas, aqua purificata, Überzug: copolymerum macrogolo et alcoholi poly(vinylico) constatum, copovidonum, e 171, kaolinum ponderosum, natrii laurilsulfas, e 110 5.9 µg, e 104, poly(alcohol vinylicus), silica colloidalis anhydrica, talcum, pro compresso obducto corresp. natrium 3 µg. - riduzione della serumcholesterinkonzentration. prevenzione di eventi cardiovascolari negli adulti con normale ldl-colesterolo e il rischio di malattie cardiovascolari aterosclerotiche. - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - rosuvastatinum - compresse rivestite con film - rosuvastatinum 10 mg ut rosuvastatinum calcicum, lactosum monohydricum 42.489 mg, calcii carbonas, cellulosum microcristallinum, crospovidonum, hydroxypropylcellulosum, magnesii stearas, aqua purificata, Überzug: copolymerum macrogolo et alcoholi poly(vinylico) constatum, copovidonum, e 171, kaolinum ponderosum, natrii laurilsulfas, e 110 2.6 µg, e 120, poly(alcohol vinylicus), silica colloidalis anhydrica, talcum, pro compresso obducto corresp. natrium 3 µg. - riduzione della serumcholesterinkonzentration. prevenzione di eventi cardiovascolari negli adulti con normale ldl-colesterolo e il rischio di malattie cardiovascolari aterosclerotiche. - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - rosuvastatinum - compresse rivestite con film - rosuvastatinum 20 mg ut rosuvastatinum calcicum, lactosum monohydricum 84.978 mg, calcii carbonas, cellulosum microcristallinum, crospovidonum, hydroxypropylcellulosum, magnesii stearas, aqua purificata, Überzug: copolymerum macrogolo et alcoholi poly(vinylico) constatum, copovidonum, e 171, kaolinum ponderosum, natrii laurilsulfas, e 110 5.1 µg, e 120, poly(alcohol vinylicus), silica colloidalis anhydrica, talcum, pro compresso obducto corresp. natrium 6 µg. - riduzione della serumcholesterinkonzentration. prevenzione di eventi cardiovascolari negli adulti con normale ldl-colesterolo e il rischio di malattie cardiovascolari aterosclerotiche. - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - rosuvastatinum - compresse rivestite con film - rosuvastatinum 40 mg ut rosuvastatinum calcicum, lactosum monohydricum 64.150 mg, calcii carbonas, cellulosum microcristallinum, crospovidonum, hydroxypropylcellulosum, magnesii stearas, aqua purificata, Überzug: copolymerum macrogolo et alcoholi poly(vinylico) constatum, copovidonum, e 171, kaolinum ponderosum, natrii laurilsulfas, e 110 5.1 µg, e 120, poly(alcohol vinylicus), silica colloidalis anhydrica, talcum, pro compresso obducto corresp. natrium 6 µg. - riduzione della serumcholesterinkonzentration. prevenzione di eventi cardiovascolari negli adulti con normale ldl-colesterolo e il rischio di malattie cardiovascolari aterosclerotiche. - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

lagap sa - rosuvastatinum - compressa rivestita con film - compressa rivestita con film: rosuvastatinum 5 mg ut rosuvastatinum calcicum, cellulosum microcristallinum, silica colloidalis anhydrica, crospovidonum, lactosum monohydricum 100.915 mg, magnesii stearas, coperta: hypromellosum, e 171, lactosum monohydricum 0.945 mg, triacetinum, e 172 (flavum) pro compresso obducto. - riduzione della concentrazione sierica di colesterolo. prevenzione degli eventi cardiovascolari negli adulti con livelli normali di colesterolo ldl e rischio aumentato di malattie cardiovascolari aterosclerotiche. - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

lagap sa - rosuvastatinum - compressa rivestita con film - compressa rivestita con film: rosuvastatinum 10 mg ut rosuvastatinum calcicum, cellulosum microcristallinum, silica colloidalis anhydrica, crospovidonum, lactosum monohydricum 95.706 mg, magnesii stearas, coperta: hypromellosum, e 171, lactosum monohydricum 1.08 mg, triacetinum, e 172 (rubrum) pro compresso obducto. - riduzione della concentrazione sierica di colesterolo. prevenzione degli eventi cardiovascolari negli adulti con livelli normali di colesterolo ldl e rischio aumentato di malattie cardiovascolari aterosclerotiche. - synthetika